Drugmaker fined by Spanish regulators $10M for 'excessive price' of rare disease drug
A company that has been under the microscope for drug pricing before has found itself fined by Spanish regulators.
Leadiant Biosciences has been
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
